Mydecine Innovations Group Inc Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

 
TIDMMYIG 
 
[A blue and white logo 
 
Description automatically generated] 
 
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth 
Market in London, UK 
 
VANCOUVER, BC, 13 October 2023 - Mydecine Innovations Group, Inc. ("Mydecine" or 
the "Company") (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology 
company engineering the next wave of innovative medications and treatment 
protocols to directly address mental health with a particular emphasis on 
addiction and PTSD, announces that it has completed its admission to the Access 
segment of the AQSE Growth Market ("AQSE") and that trading commenced at 8:00 
A.M. GMT on Tuesday, 10 October 2023 ("Admission") under the ticker "MYIG". 
 
Company Highlights: 
 
-      Mydecine Innovations Group Inc. is an emerging biotech and life sciences 
company dedicated to developing and commercializing innovative solutions for 
treating mental health problems and enhancing wellbeing. 
 
-      The Companies various families of Novel 2nd generation molecules are 
showing significant improvements over the first generation of psychedelic 
treatments.  The Company has taken the approach that, in order to have a truly 
successful drug that is accessible by all, numerous modifications need to be 
made to the first generation MDMA or Psilocybin molecules, most notably 
shortening the half-life while keeping the experience integrity intact. 
 
-      The Company is currently working with its pre-clinical team at the 
University of Alberta to work these molecules through the Investigational New 
Drug enabling stage with the intent to put them into human clinical studies 
expected to commence in 2024. 
 
-      The Company has a comprehensive intellectual property strategy covering 
novel molecules, drug formulations, delivery mechanisms, and methods of 
production. The Company believes this covers all described drug development 
activities in our named pipeline and clinical trials. The Company has filed 
these applications both in the United States and through the Patent Cooperation 
Treaty (PCT) for protection in all jurisdictions in which the Company does 
business. 
 
Management Commentary: 
 
Josh Bartch, CEO of the Company stated, "We are incredibly excited to list our 
securities for trading in the UK on the AQSE Growth Market.  We believe Mydecine 
is at a pivotal phase in its development and look forward to increased exposure 
to UK and European investors alike". 
 
The Company will have a dual listing with its common shares fully fungible 
through a CREST Depositary Interest ("CDI"). The CDIs will carry the same ISIN 
as the Common Shares listed in Canada on NEO. The issued share capital of 
Mydecine comprises 45,207,458 common shares. 
 
Sector Classification: 
 
The Company is classified as a Healthcare company on the Access Segment of the 
Aquis Stock Exchange. 
 
This announcement, together with any documents incorporated by reference, shall 
be deemed to constitute an admission document for the purposes of the AQSE 
Growth Market Rules for Issuers - Access. It has not been approved or reviewed 
by the Aquis Stock Exchange or the Financial Conduct Authority. 
 
The Directors are of the opinion, having made due and careful enquiry, that the 
working capital available to the Company is sufficient for a period of at least 
twelve months following admission. 
 
The Directors of Mydecine take responsibility for this announcement. 
 
This announcement contains inside information for the purposes of Article 7 of 
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by 
virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in 
accordance with the Company's obligations under Article 17 of MAR. 
 
Learn more 
athttps://www.mydecine.com (https://www.globenewswire.com/Tracker?data=pYYeIgyfJN 
ztJyMdZZn-VpwxQrtBtlSMsGBtRIzOm4yDrnPjpMN70JuFZb5zwysliiTHd1E 
-OMW5uy96TYKYq3DlZw4jl7g9-VpYCutSPw4=). 
 
For more information, please contact: 
 
Mydecine Innovations Group, Inc. 
 
Media Contactpr@mydecineinc.com 
 
Investor Relations investorrelations@mydecineinc.com 
 
On behalf of the Board of Directors 
 
Josh Bartch, Chief Executive Officer 
 
contact@mydecineinc.com (https://www.globenewswire.com/Tracker?data=XgmGtylsXA6VF 
sl1t2XonXZxbdxgRJ4U5xUxRn_br82rGamHAHV8ETBkWYjJ90rG4PQcbbMn 
-Muh8TkDqd7fyAwbkuzhVWKsnIOxGJ28TYQ=) 
 
AQSE Corporate Advisor 
 
Novum Securities LimitedTel: +44 (0)207 399 9400 
 
David Coffman/ George Duxberry 
 
For further information about Mydecine Innovations Group, Inc., please visit the 
Company's profile on SEDAR+ 
atwww.sedarplus.com (https://www.globenewswire.com/Tracker?data=YNj_VUl08q2SdnpWe 
pGzP3_YOOiKuzJJrbnxDXCI1Leg1akLusipFW1vhWR1aMjJftNI 
-Ah9OB2usnxVGSZ9KjqGwZNlR0P0XR3WIK5FFxY=)or the Company's website 
atwww.mydecine.com (https://www.globenewswire.com/Tracker?data=Dj2LE9v1Uzwr24a2BH 
YMvXXmH94foLuMzvU__Lx5l3lzIOt3KMiShtj466xDkP89HTMUQUkeFIRxVLGRmv66iA==). 
 
About Mydecine Innovations Group Inc. 
 
Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical 
company that began operations in North America and Europe in early 2020. 
Mydecine was founded to increase physicians' access to serotonin-modulating 
medicine. Recent research has demonstrated the therapeutic potential of 
psychedelic substances such as psilocybin and MDMA for treating intractable 
conditions such as pain, anxiety, depression, addiction, and PTSD, along with 
neurodegenerative disorders. Mydecine believes these compounds can be safer, 
more effective, and more accessible for patients and medical professionals 
through modern drug chemistry paired with artificial intelligence (AI). Mydecine 
is developing innovative medications for target indications with high mortality 
rates that have lacked innovation for decades and are controlled by dominant 
corporations. Mydecine developed several prodrug families, beginning with a 
psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at 
Johns Hopkins University. Mydecine is also developing MYCO-006-short-acting 
chemical analogs derived from MDMA for treating various conditions, including 
anxiety and pain. Mydecine utilises cutting-edge artificial intelligence (AI) 
and pharma research infrastructure at the University of Alberta to develop and 
manufacture new medications to make them affordable and accessible to the 
general public upon Health Canada and FDA approval. The Mydecine team is 
enthusiastic about its mission and is dedicated to creating a positive 
difference in the lives of others. 
 
Directors: 
 
Josh Bartch, Chief Executive Officer and Chairman 
 
Josh Bartch is Director, Chief Executive Officer, and Chairman of Mydecine 
Innovations Group (MIG). His entrepreneurial career commenced in 2009 when he 
cofounded AudioTranscriptionist.com and founded the Denver-based dispensary, 
Doctors Orders. Following these ventures, Josh founded a boutique investment 
firm that operated throughout the U.S. and Canadian markets. In 2014, he co 
-founded Cannabase.io, the U.S.'s most significant legal and sophisticated 
cannabis wholesale platform. He made successful exits from 
AudioTranscriptionist.com, Doctor's Orders, and Cannabase.io. 
 
Robert Roscow, Chief Science Officer 
 
Robert is Chief Science Officer of Mydecine bringing his diverse background in 
biology, biotechnology, policy and intellectual property to innovation in the 
mycology space. Robert's substantial expertise includes genetic engineering, 
molecular biology, bioinformatics, plant breeding and tissue culture, 
photomicroscopy, unicellular microinjection, fish husbandry and breeding colony 
maintenance and 
 
transfection. 
 
Following academic work studying the genetic dynamics of cellular patterning, 
Robert applied his advanced knowledge to cannabis plant enhancement. He joined 
ebbu in 2015, where he created IP related to the commercial optimisation of 
Cannabis sativa, industrial hemp and hops, resulting in three pending US 
patents. 
 
In 2019 Rob oversaw the design, build and staffing of a plant analytical 
chemistry laboratory in Ontario, Canada, for Canopy Growth Corporation where he 
was Lead Director of Genetic Research. He also participated in the Colorado Hemp 
Advancement & Management Plan Initiative Cannabis Industry as an industry 
stakeholder in 2019. 
 
Neil Stevenson-Moore, Non-Executive Director 
 
Neil is an experienced executive and thought leader in the technology community. 
He has a track record of driving growth, success and innovation and has worked 
in both corporate and entrepreneurial environments. For the past 15 years he has 
founded, led, and advised companies in consumer focused and medical tech 
industries including House of Kibaa, SportNinja, Farfetch and StylePixi He has 
successfully raised tens of millions of dollars from private investors, 
community partners, and government organisations. Neil holds a Bachelor of 
International Politics from Princeton University and has additional coaching 
certifications. He is fluent in French and proficient in Spanish. 
 
Forward-looking Information 
 
This news release contains forward-looking information about Canadian securities 
laws regarding the Company and its business. It relates to future events or 
performance and reflects management's expectations and assumptions. Often but 
not always, forward-looking information can be identified by the use of words 
such as "expect," "intends," "anticipated," "believes," or variations (including 
negative variations) of such words and phrases or by stating that specific 
actions, events, or results "may," "could," "would," or "will" be taken, occur, 
or be achieved. 
 
Such forward-looking statements reflect management's beliefs and are based on 
assumptions and information currently available to the Company. Readers are 
cautioned that these forward-looking statements are neither promises nor 
guarantees and are subject to risks and uncertainties that may cause future 
results to differ materially from those expected, including, without limitation,

risks regarding the COVID-19 pandemic, the availability and continuity of 
financing, the ability of the Company to protect and enforce its intellectual 
property adequately, the Company's ability to bring its products to commercial 
production, the continued growth of the global adaptive pathway medicine, 
natural health products, and digital health industries, and the risks presented 
by the highly regulated and competitive market concerning the development, 
production, sale, and use of the Company's products. Although the Company has 
attempted to identify important factors that could cause actual results to 
differ materially from those contained in forward-looking information, other 
factors may cause effects not to be as anticipated, estimated, or intended. 
There can be no assurance that such information will be accurate, as actual 
results and future events could differ materially from those anticipated. These 
forward-looking statements are made as of the date hereof. The Company is not 
obligated to update or revise them to reflect new events or circumstances as 
required under applicable securities legislation. 
 
This news release shall not constitute an offer to sell or the solicitation of 
an offer to buy nor shall there be any sale of the securities in any State in 
which such offer, solicitation or sale would be unlawful. The securities being 
offered have not been, nor will they be, registered under the United States 
Securities Act of 1933, as amended, and may not be offered or sold in the United 
States absent registration or an applicable exemption from the registration 
requirements of the United States Securities Act of 1933, as amended, and 
applicable state securities laws. 
 
MYDECINE INNOVATIONS GROUP, INC. 
Suite 810-789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604 
-687-2038 
 
 
This information was brought to you by Cision http://news.cision.com 
https://news.cision.com/mydecine-innovations-group-inc/r/mydecine-innovations-group-announces-admission-to-trading-on-the-aqse-growth-market-in-london--uk,c3853743 
The following files are available for download: 
https://news.cision.com/mydecine-innovations-group-inc/i/3853743-0-png,c3225468 3853743_0.png 
 
 
END

(END) Dow Jones Newswires

October 13, 2023 13:06 ET (17:06 GMT)

Mydecine Innovations (AQSE:MYIG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024